CBN Perspective丨From lemons to legends: How Mixue shatters the “IPO spell” on tea drinks
On its first day of trading on the Hong Kong Stock Exchange, Mixue’s stock price surged by a whopping 43.2%, closing at ...
Scotiabank给予Perspective Therapeutics"板块超越大盘"评级，目标价15美元
周五，Scotiabank开始对Perspective Therapeutics Inc (NYSE: CATX )股票进行覆盖，给予"板块超越大盘"评级，并设定目标价为15.00美元。目前该股交易价格为2.70美元，远低于分析师6美元至21美元的目标价区间。作为业内为数不多的独立放射性药物公司之一，Perspective Therapeutics获得了Scotiabank的关注。